Ramiro Gilardino

Rigorous, transparent and inconclusive: what Europe’s first joint clinical assessment reveals about a framework trying to serve everyone

On 30 April 2026, the Member State Coordination Group on Health Technology Assessment endorsed Europe’s first joint clinical assessment (JCA) under Regulation (EU) 2021/2282, evaluating tovorafenib (Ojemda) for pediatric low-grade glioma harboring BRAF alterations. This perspecti...